pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
APHP210084
Phase 2 · small molecule · first suspected infection with Mycobacterium tuberculosis in the lungs
APHP210084 for first suspected infection with Mycobacterium tuberculosis in the lungs is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP210084
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- first suspected infection with Mycobacterium tuberculosis in the lungs
- Status
- active
- Trials
- 1